Key Insights

Highlights

Success Rate

81% trial completion

Published Results

30 trials with published results (18%)

Research Maturity

74 completed trials (45% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

10.3%

17 terminated out of 165 trials

Success Rate

81.3%

-5.3% vs benchmark

Late-Stage Pipeline

7%

12 trials in Phase 3/4

Results Transparency

41%

30 of 74 completed with results

Key Signals

30 with results81% success17 terminated

Data Visualizations

Phase Distribution

110Total
Not Applicable (40)
P 1 (26)
P 2 (32)
P 3 (12)

Trial Status

Completed74
Recruiting33
Terminated17
Unknown16
Active Not Recruiting11
Not Yet Recruiting10

Trial Success Rate

81.3%

Benchmark: 86.6%

Based on 74 completed trials

Clinical Trials (165)

Showing 20 of 20 trials
NCT07059884Not ApplicableRecruiting

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT04708470Phase 1Completed

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

NCT06263088Not ApplicableRecruiting

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

NCT07775209Phase 2Enrolling By InvitationPrimary

Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma

NCT05858736Phase 1Completed

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

NCT05109468CompletedPrimary

Assessment of Patients' Quality of Sexual Life After Anal Cancer Treatment

NCT07795801Not ApplicableNot Yet Recruiting

Mind-Body Sexual Well-Being Program for Female GI Cancer Survivors

NCT06904365Recruiting

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

NCT07782164Recruiting

Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)

NCT07790601Not ApplicableNot Yet RecruitingPrimary

Swabs in Screening for HPV (SWISH)

NCT07090174Phase 2Withdrawn

CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV

NCT04432597Phase 1Completed

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

NCT04230759Phase 2Active Not RecruitingPrimary

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

NCT05510908Completed

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

NCT07425054Phase 2RecruitingPrimary

ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer

NCT06493019Phase 2RecruitingPrimary

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

NCT07696169Not Yet Recruiting

Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers

NCT05628194Active Not RecruitingPrimary

ASSESSING THE GAY MALE EXPERIENCE WITH ANAL CANCER PREVENTION STRATEGIES

NCT04287868Phase 1Completed

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

Scroll to load more

Research Network

Activity Timeline